Sugi Predict

Sugi Predict / Compounds / SCHEMBL9497417

SCHEMBL9497417

SCHEMBL9497417

CCCCCCCCCCCCCCCCSCCCO

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.60
▸ HSD17B10 Q99714 2/20 0.60
▸ ALDH1A1 P00352 2/20 0.60
▸ TSHR P16473 2/20 0.60
▸ MEN1 O00255 1/20 0.60
▸ KMT2A Q03164 1/20 0.60
▸ SMN1; SMN2 Q16637 1/20 0.55
▸ CES2 O00748 3/20 0.52
▸ THRB P10828 2/20 0.52
▸ GMNN O75496 1/20 0.52
▸ TP53 P04637 1/20 0.52
▸ POLB P06746 1/20 0.52
▸ MAPT P10636 1/20 0.52
▸ CYP2C9 P11712 1/20 0.52
▸ BLM P54132 1/20 0.52
▸ FAAH O00519 4/20 0.45
▸ CES1 P23141 4/20 0.45
▸ PLA2G6 O60733 1/20 0.45
▸ CA2 P00918 1/20 0.45
▸ PRKD3 O94806 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28228178 1.00 LMNA (0.60) LMNAHSD17B10ALDH1A1TSHRMEN1
SCHEMBL10914879 1.00 LMNA (0.60) LMNAHSD17B10ALDH1A1TSHRMEN1
SCHEMBL11084664 1.00 LMNA (0.60) LMNAHSD17B10ALDH1A1TSHRMEN1
SCHEMBL11426384 1.00 LMNA (0.60) LMNAHSD17B10ALDH1A1TSHRMEN1
SCHEMBL8497025 1.00 LMNA (0.60) LMNAHSD17B10ALDH1A1TSHRMEN1
SCHEMBL24140148 1.00 LMNA (0.60) LMNAHSD17B10ALDH1A1TSHRMEN1
SCHEMBL11082902 1.00 LMNA (0.60) LMNAHSD17B10ALDH1A1TSHRMEN1
SCHEMBL14814301 1.00 LMNA (0.60) LMNAHSD17B10ALDH1A1TSHRMEN1
SCHEMBL11088058 1.00 LMNA (0.60) LMNAHSD17B10ALDH1A1TSHRMEN1
SCHEMBL25956429 1.00 LMNA (0.60) LMNAHSD17B10ALDH1A1TSHRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-3169848-A — — None — — JP disclosed
EP-3730503-B1 ANTIVIRAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR SHENZHEN TARGETRX INC (CN) 2026-01-28 — — EP disclosed
US-12208110-B2 Phospholipid compounds and uses thereof GILEAD SCIENCES, INC. (US) 2025-01-28 — — US disclosed
US-20240360163-A1 Nucleoside Prodrugs and Uses Related Thereto UNIV EMORY (US) 2024-10-31 — — US disclosed
US-12049474-B2 Nucleoside prodrugs and uses related thereto EMORY UNIVERSITY (US) 2024-07-30 — — US disclosed
CN-118388535-A Nucleoside analogue sulfur-containing fatty chain phosphonate compound, composition, preparation method and application thereof 中国人民解放军军事科学院军事医学研究院 2024-07-26 — — CN disclosed
US-11963967-B2 Phospholipid compounds and uses thereof GILEAD SCIENCES, INC. (US) 2024-04-23 — — US disclosed
EP-4228685-A1 PHOSPHOLIPID COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2023-08-23 — — EP disclosed
US-20230248753-A1 PHOSPHOLIPID COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. 2023-08-10 — — US disclosed
US-20230248753-A1 PHOSPHOLIPID COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. 2023-08-10 — — US disclosed
WO-2021035214-A1 NUCLEOSIDE PRODRUGS AND USES RELATED THERETO EMORY UNIVERSITY (US) 2021-02-25 — — WO disclosed
US-20200369696-A1 ANTIVIRAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR SHENZHEN TARGETRX, INC. (CN) 2020-11-26 — — US disclosed
EP-3730503-A1 ANTIVIRAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR Shenzhen TargetRx, Inc. (CN) 2020-10-28 — — EP disclosed
US-5208223-A Enzyme inhibitors AMERICAN CYANAMID COMPANY (US) 1993-05-04 — — US disclosed
US-5144045-A Treatment of inflammatory related disorders AMERICAN CYANAMID COMPANY (US) 1992-09-01 — — US disclosed
JP-H03169848-A ORGANIC SULFIDE ANTIOXIDANTS ATOCHEM NORTH AMERICA INC 1991-07-23 — — JP disclosed
EP-0426144-A1 Organic sulfide antioxidants ATOCHEM NORTH AMERICA, INC. (US) 1991-05-08 — — EP disclosed
EP-0050327-B1 PHOSPHOLIPIDS THAT CONTAIN SULPHUR, PROCESS FOR THEIR PREPARATION AND MEDICINES CONTAINING THESE COMPOUNDS Roche Diagnostics GmbH (DE) 1984-06-20 — — EP disclosed
US-4444766-A ANTITUMOR BOEHRINGER MANNHEIM GMBH (DE) 1984-04-24 — — US disclosed
EP-0050327-A1 Phospholipids that contain sulphur, process for their preparation and medicines containing these compounds Roche Diagnostics GmbH (DE) 1982-04-28 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240360163-A1 Nucleoside Prodrugs and Uses Related Thereto PNPO, GSTO1, CYP2C18 LMNA 1862/4885HSD17B10 322/4885ALDH1A1 735/4885
US-12049474-B2 Nucleoside prodrugs and uses related thereto PNPO, GSTO1, CYP2C18 LMNA 1862/4885HSD17B10 322/4885ALDH1A1 735/4885
US-12208110-B2 Phospholipid compounds and uses thereof PHOSPHO1, SGMS1, SGMS2 LMNA 1163/4885HSD17B10 1118/4885ALDH1A1 3479/4885
US-20230248753-A1 PHOSPHOLIPID COMPOUNDS AND USES THEREOF PHOSPHO1, SGMS2, SGMS1 LMNA 1062/4885HSD17B10 2157/4885ALDH1A1 3784/4885
US-20200369696-A1 ANTIVIRAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR TYMP, HPRT1, POLRMT LMNA 1867/4885HSD17B10 478/4885ALDH1A1 1382/4885
US-11963967-B2 Phospholipid compounds and uses thereof PHOSPHO1, SGMS2, SGMS1 LMNA 1062/4885HSD17B10 2157/4885ALDH1A1 3784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.